Sažetak
Uvod/Cilj. Pegilovani interferon (PEG-IFN) alfa-2a je registrovan u Srbiji od 2013. godine za lečenje bolesnika sa hroničnim hepatitisom B (HHB). S obzirom na njegove mnogobrojne prednosti u odnosu na dotadašnju terapiju, nova iskustva u periodu od proteklih pet godina i nedostatak publikovanih rezultata u našoj populaciji, cilj rada bio je da se prvi put među bolesnicima sa HHB u Srbiji ispita efikasnost i bezbednost primene PEG-IFN u tercijarnoj zdravstvenoj ustanovi. Metode. U prospektivnoj studiji u petogodišnjem periodu od 2012. do 2017. godine analizirano je ukupno 36 bolesnika sa HHB, lečenih standardnim protokolom PEG-IFN tokom 48 nedelja, u Hepatološkom odeljenju Klinike za infektivne i tropske bolesti Kliničkog centra Srbije u Beogradu. Svim bolesnicima su merene bazalne vrednosti transaminaza, serologije i viremije, uključujući praćenje tih parametara tokom terapije, na kraju terapije i u periodu praćenja. Za procenu uspeha terapije analiziran je serološki odgovor (gubitak HBeAg), biohemijski odgovor [normalizacija alanin aminotransferaze (ALT)] i virusološki odgovor na terapiju [supresija DNK hepatitis B virusa (HBV) < 2000 IU/mL. Rezultati. Virusološki uspeh terapije kod bolesnika sa HBeAg pozitivnim HHB postignut je kod 50% bolesnika, gubitak HBeAg kod 62,5%, a biohemijski odgovor kod 37,5% bolesnika. Kod HBeAg negativnog HHB, virusološki uspeh terapije postignut je kod 38% bolesnika, biohemijski odgovor kod 47,6%, a samo jedan (4,7%) bolesnik imao je i gubitak HBsAg. Zaključak. Primena PEG-IFN u lečenju HBV infekcije važna je u dobro selektovanoj grupi bolesnika, a u našoj populaciji lečenih bolesnika procenat uspešnosti terapije sličan je onom od drugih autora. Bezbednost i podnošljivost terapije je dobra, ali se mogu očekivati i ozbiljniji neželjeni događaji zbog čega je neophodno redovno praćenje bolesnika tokom lečenja.
Ključne reči
Array
Array
Array
Array
Array
Array
Reference
European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57(1): 167–85.
European Association for the Study of the Liver. EASL 2017 Clini-cal Practice Guidelines on the management of hepatitis B vi-rus infection. J Hepatol 2017; 67(2): 370–98.
Health Insurance Fund of the Republic of Serbia. List C. Drugs with a special regime of release. [Cited 2018 May 30] Available from: https://www.rfzo.rs/download/pravilnici/lekovi/Lista %20Cprimena%20od%2001.01.2018..pdf
Sonnevald MJ, Hansen BE, Piratvisuth T, Jia J, Zeuzem S, Gane E, et al. Response guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen level. Hepatology 2013; 58(3): 872–80.
Chon YE, Kim DJ, Kim SG, Kim HG, Bae SH, Hwang SG, et al. An observational, muticenter, cohort study evaluating the an-tiviral efficacy and safety in korean patients with chronic hep-atitis B receiving pegylated interferon-alfa 2a (Pegasys). Medi-cine 2016; 95(14): e3026.
Vlachogiannakos J, Papatheodoridis GV. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int 2015; 35(Suppl 1): 100–6.
Lampertico P, Rothe V, Caputo A, Papatheodoridis GV. A base-line predictive tool for selecting HBeAg-negative chronic hep-atitis B patients who have a high probability of achieving sus-tained immune control with peginterferon alfa-2a. Hepatology 2014; 60: 1107A.
Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int 2015; 35(5): 1540–8.
Milosevic I, Delic D, Lazarevic I, Pavlovic IP, Korac M, Bojovic K, Jevtovic D. The significance of hepatitis B virus (HBV) geno-types for the disease and treatment outcome among patients with chronic hepatitis B in Serbia. J Clin Virol 2013; 58(1): 54–8.
Bojović K, Božić M, Stanojević B, Popović N. The first resultsof genotyping hepatitis B virus in Serbia and Montenegro, Falk symposium 157 Chronic Hepatitis: metabolic, Cholestatic, Vi-ral and Autoimmune. Freibug; 2006. Abstracts 21.
Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol 2015; 63(5): 1238–53.
Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, et al. Hepatitis B surface antigen levels: associa-tion with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013; 7(1): 88–97.
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term fol-low-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135(2): 459–67.
Piratvisuth T, Marcellin P, Brunetto M, Bonino F, Farci P, Yurday-din C, et al. Sustained immune control 1 year post-treatment with Peginterferon Alfa -2a [40KD] (PEGASYS) is durable up to 5 years post-teratment and is associated with a hihg rate of HBsAg clearance in HbeAg-negative chronic hepatitis B. 20th Conference of the Asian Pacific Asspciation for the Study of the Liver (APASL); Bejing, China 2010 March 25–28.
Vigano M, Invernizzi F, Lampertico P. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative pa-tients? Liver Int 2015; 35(Suppl 1): 107–13.
Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, et al. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS One 2015; 10(4): e0122259.
Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, et al. Validation of a stopping rule at week 12 us-ing HBsAg and HBV DNA for HBeAg-negative patients treat-ed with peginterferon alfa-2a. J Hepatol 2012; 56(5): 1006–11.
Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013; 62(2): 290–8.